Please login to the form below

Not currently logged in
Email:
Password:

ABPI appoints value and access manager

Christine Rowland joins from Pfizer
ABPI_Christine-Rowland

Christine Rowland has been appointed to the newly created position of value and access manager at the Association of the British Pharmaceutical Industry (ABPI).

Rowland will work on a range of projects to improve patient access to innovative medicines, in line with the ABPI's strategic objectives around health technology assessment and market access.

Rowland joins the ABPI from Pfizer where she spent 12 years in a range of roles, including sales, marketing, and market access, covering areas such as oncology and rare diseases. In addition to 17 years in the pharmaceutical industry, Rowland spent a decade with the NHS as a nurse and midwife.

“I am delighted to join the ABPI at this time of great change in the landscape of the UK health system and the NHS,” Rowland said.

The new role will see her join the ABPI's 23-strong commercial department. ABPI director of value and access Paul Catchpole said Rowland was a very welcome addition to the team at a time when the APPI is leading an increasing number of commercial initiatives.

“These include the implementation of the new PPRS scheme, working with NICE on value based assessment and helping our members with the changing NHS landscape whilst continuing to push for greater use of newer medicines,” added Catchpole.

15th May 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics